Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." in Essential Blepharospasm
Double-blinded, Randomized, Active Control Comparative, Parallel-designed, Phase III Clinical Trial: Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." In Essential Blepharospasm Running Parallel With Phase I Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bundang, Korea, Republic of
- Cha Hospital
-
Bundang, Korea, Republic of
- Seoul National University Hospital - Bundang
-
Daegu, Korea, Republic of
- Youngnam University Hospital
-
Seoul, Korea, Republic of
- Samsung Medical Center
-
Seoul, Korea, Republic of
- Chungang University Hospital
-
Seoul, Korea, Republic of
- Kim's Eye Hospital
-
Seoul, Korea, Republic of
- The Catholic University, Seoul, St.Mary's hospital
-
Seoul, Korea, Republic of
- The catholic university, Yeouido, St. Mary's hospital
-
Seoul, Korea, Republic of
- Yeonsei University, Severance hospital - Gangnam
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult between ages 18 and 75 years
- All patients, diagnosed of essential blepharospasm, with Grade 2~4 of Severity of Spmasm (by Scott's Method)
Exclusion Criteria:
- Patients have undergone surgical surgery to treat blepharospmasm like myectomy or neurectomy
- Patients with hypersensitivity history to botulinum toxin products previously
- Patients with secondary blepharomspasm
- Patients with hemifacialspasm
- Patients with treatment following drugs ; Anticonvulsants, tranquilizers, narcotics, aminoglycoside antibiotics, muscle relaxtants like baclofen etc., blockers of parasympathetic nervous system, levodopa
- Patients with previous injection of other botulinum toxin products in 3 months
- Patients with any other significant neuromuscular disease like Myasthenia gravis
- Pregnant or breastfeeding women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Botulinum toxin type A(Botox®)
|
1.25U~2.5U/site,
Maximum dosage 12.5U~60U/person
1.25U~2.5U/site,
Maximum dosage 12.5U~60U/person
|
|
Experimental: Botulinum toxin type A(Hugeltox)
|
1.25U~2.5U/site,
Maximum dosage 12.5U~60U/person
1.25U~2.5U/site,
Maximum dosage 12.5U~60U/person
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Rate of patients with an improvement more than one Grade of Severity of Spasm (by Scott's Method)
Time Frame: at 4 weeks post-injection
|
at 4 weeks post-injection
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
(1) Duration of action days
Time Frame: 6 months
|
6 months
|
|
(2) Grades of Severity of Spasm (by Scott's Method), Functional Visual Status
Time Frame: at four weeks post-injection
|
at four weeks post-injection
|
|
(3) Rate of patients with a Grade-0 or Grade-1 of Severity Spasm (by Scott's Method)
Time Frame: at four weeks post-injection
|
at four weeks post-injection
|
|
(4) Rate of patients with an improvement more than two Grade of Severity of Spasm (by Scott's Method)
Time Frame: at four weeks post-injection
|
at four weeks post-injection
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Yoon-Duck Kim, M.D., Ph.D., Samsung Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Eyelid Diseases
- Blepharospasm
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
Other Study ID Numbers
- HG-06-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.